Suppr超能文献

非普拉宗减轻白细胞介素-1β诱导的软骨细胞衰老。

Feprazone Mitigates IL-1β-Induced Cellular Senescence in Chondrocytes.

作者信息

Huang Zhusong, Lan Jinfu, Gao Xi

机构信息

Department of Orthopaedics, Fuzhou Second Hospital of Xiamen University, No. 47 Shangteng Road, Cangshan District, Fuzhou, Fujian 350007, China.

出版信息

ACS Omega. 2021 Mar 31;6(14):9442-9448. doi: 10.1021/acsomega.0c06066. eCollection 2021 Apr 13.

Abstract

The proinflammatory cytokine interleukin-1 β (IL-1β)-mediated cellular senescence in chondrocytes is involved in the development and pathological progression of osteoarthritis (OA). Feprazone, a nonsteroidal anti-inflammatory drug (NSAID) and a cyclooxygenase (COX) inhibitor, is widely used in clinics. This study aims to investigate whether Feprazone has a protective effect against IL-1β-induced cellular senescence in human chondrocytes. In this study, C-28/I2 chondrocytes were stimulated with IL-1β (10 ng/mL) in the presence or absence of Feprazone (10 and 20 μM). Cellular senescence was assessed using senescence-associated β-galactosidase (SA-β-Gal) staining. The cell cycle was examined using flow cytometry. Gene and protein expressions were determined with real-time polymerase chain reaction (PCR) and western blot analysis. We found that treatment with Feprazone ameliorated IL-1β-induced increase in cellular senescence. Feprazone increased telomerase activity and prevented cell cycle arrest in the G0/G1 phase. We also found that Feprazone reduced the expressions of plasminogen activator inhibitor-1 (PAI-1) and p21, two important regulators of cellular senescence. Additionally, treatment with Feprazone reduced the expressions of matrix metalloprotein (MMP-13) and a disintegrin-like and metalloproteinase with thrombospondin type-1 motif-5 (ADAMTS-5). Interestingly, Feprazone prevented the activation of nuclear factor kappa-B (NF-κB) by preventing nuclear translocation of NF-κB p65 and the luciferase activity of the NF-κB promoter. The results also show that Feprazone increased nuclear levels of nuclear factor erythroid 2-related factor-2 (Nrf2) and reduced the production of reactive oxygen species (ROS). Importantly, silencing of Nrf2 abolished the protective effects of Feprazone against IL-1β-induced NF-κB activation and cellular senescence. These findings shed light on the potential use of Feprazone in the treatment of OA based on a novel mechanism.

摘要

促炎细胞因子白细胞介素-1β(IL-1β)介导的软骨细胞衰老参与骨关节炎(OA)的发生发展及病理进程。非甾体抗炎药(NSAID)及环氧化酶(COX)抑制剂非普拉宗在临床上广泛应用。本研究旨在探究非普拉宗对IL-1β诱导的人软骨细胞衰老是否具有保护作用。在本研究中,在存在或不存在非普拉宗(10和20 μM)的情况下,用IL-1β(10 ng/mL)刺激C-28/I2软骨细胞。使用衰老相关β-半乳糖苷酶(SA-β-Gal)染色评估细胞衰老。通过流式细胞术检测细胞周期。用实时聚合酶链反应(PCR)和蛋白质印迹分析确定基因和蛋白质表达。我们发现,非普拉宗处理改善了IL-1β诱导的细胞衰老增加。非普拉宗增加端粒酶活性并防止细胞周期停滞在G0/G1期。我们还发现,非普拉宗降低了纤溶酶原激活物抑制剂-1(PAI-1)和p21的表达,这是细胞衰老的两个重要调节因子。此外,非普拉宗处理降低了基质金属蛋白酶(MMP-13)和具有血小板反应蛋白基序的解聚素样金属蛋白酶-5(ADAMTS-5)的表达。有趣的是,非普拉宗通过阻止NF-κB p65的核转位和NF-κB启动子的荧光素酶活性来阻止核因子κB(NF-κB)的激活。结果还表明,非普拉宗增加了核因子红细胞2相关因子2(Nrf2)的核水平并减少了活性氧(ROS)的产生。重要的是,Nrf2沉默消除了非普拉宗对IL-1β诱导的NF-κB激活和细胞衰老的保护作用。这些发现基于一种新机制揭示了非普拉宗在OA治疗中的潜在用途。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2399/8047674/448882cd451f/ao0c06066_0002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验